Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway

Abstract

Preexisting hypertension, age, and BMI identify patients at risk for significant anti-VEGF therapy-induced BP elevation. Hypertension appears to be a clinical biomarker of efficacy of anti-VEGF therapies in a broad range of malignancies.